Calcium Supplement by Tetracycline guided amorphous Calcium Carbonate potentiates Osteoblast promotion for Synergetic Osteoporosis Therapy

Wang, Jianwei; Tao, Shifei; Jin, Xuesong; Song, Yanqing; Zhou, Wentao; Lou, Heqiang; Zhao, Rui; Hu, Fuqiang; Yuan, Hong

doi:10.7150/thno.45142

Cited by 26 publications

(16 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As displayed in Figure A, the cellular Ce6 intensity was positively related to the treating time. Moreover, as compared to two nanoparticles, the accumulation of free Ce6 in cells was the lowest among all three experimental groups, indicating that the introduction of DDS can significantly increase the accumulation of drugs in cells and was also consistent with previous reports . Additionally, in the absence of FA, the FA-Lipo-Ce6 group showed a higher cellular Ce6 level than Lipo-Ce6 at all given time points.…”

Section: Results and Discussionsupporting

confidence: 91%

“…Moreover, as compared to two nanoparticles, the accumulation of free Ce6 in cells was the lowest among all three experimental groups, indicating that the introduction of DDS can significantly increase the accumulation of drugs in cells and was also consistent with previous reports. 35 Additionally, in the absence of FA, the FA-Lipo-Ce6 group showed a higher cellular Ce6 level than Lipo-Ce6 at all given time points. Interestingly, the intracellular Ce6 intensity of the FA-Lipo-Ce6 group decreased sharply after folic acid pretreatment, while the free Ce6 and Lipo-Ce6 groups exerted insignificant changes.…”

Section: ■ Results and Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy

Pan

Shi

et al. 2021

ACS Omega

View full text Add to dashboard Cite

Cancer vaccine is well recognized as a promising approach for immunotherapy of cancers. Since dendritic cells (DCs) are capable of processing and presenting antigens to initiate the immune response cascade, the development of DC vaccines is considered as a good choice for the treatment of cancer. Herein, a folic acid (FA)-modified liposome was constructed and loaded with chlorin e6 (Ce6) as a DC vaccine (FA-Lipo-Ce6). It was suggested that the loaded Ce6 within FA-Lipo-Ce6 can be activated under laser irradiation. The photodynamic therapy (PDT) of Ce6 was expected to create on-demand reactive oxygen species (ROS) in situ, which causes cell death and trigger the exposure of tumorassociated antigen (TAA). In addition, the produced ROS can mimic the inflammatory responses for the employment of DC for better antigen presentation and immune response. Most importantly, the employment of DC can recognize the exposed TAA to stimulate DC for effective vaccination in situ. Our results demonstrated the powerful capacity of FA-Lipo-Ce6 to induce DC activation, leading to effective suppression of the growth of breast cancers.

show abstract

Section: Results and Discussionsupporting

confidence: 91%

Section: ■ Results and Discussionmentioning

confidence: 83%

Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy

Pan

Shi

et al. 2021

ACS Omega

View full text Add to dashboard Cite

show abstract

“… 20 Absorption issues aside, evidence suggests that most of ingested calcium may be excreted before reaching the targeted osteoporotic tissues. 21 To overcome this problem, calcium administration with adjuvant therapy is recommended. Moreover, some researchers suggest that ionic calcium supplements such as antiorbital ionic calcium may provide greater benefit to osteoporosis patients than conventional calcium intake.…”

Section: Discussionmentioning

confidence: 99%

Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures

Aypak¹,

Bircan²,

Özdemir³

2022

Rambam Maimonides Med J

View full text Add to dashboard Cite

Objectives: Anti-osteoporotic drugs (AOD) are essential for secondary prevention of osteoporotic fracture (OF) in patients with established osteoporosis. However, data about AOD utilization rates are scarce among patients with OF. This study was therefore aimed at determining the AOD utilization rates among those particularly vulnerable patients. Materials and Methods: This cross-sectional study followed the medical records of patients with OF starting from their first OF diagnosis date. Each patient’s preventive osteoporosis treatments (vitamin D, calcium+vitamin D) and AOD utilization rate were recorded for a 12-month period following OF diagnosis. Results: A total of 210 patients (168 females, mean age: 67.8±11.9 years; 42 males, mean age 62.4±16.1 years) were enrolled in the study. Of these, 65.7% (n=138) did not use any medication for primary protection against osteoporosis before OF diagnosis. The ratio of patients not using any type of medication for secondary prevention after OF increased from 26.5% to 51% during a 12-month period. In addition, by one year following diagnosis, AOD usage rate had decreased from 62.3% to 41.3%. Conclusion: The AOD usage rates for secondary prevention of OF were insufficient, and cessation rates were high. Identification of factors associated with decreased AOD utility rates will provide important information for guiding patient follow-up in order to reduce the occurrence of OF.

show abstract

“…The small peak in the HPLC chromatogram of ACMP/SIM solution clearly reveals the existence of SIM in the nanocomposites and the content is 1.311 mg g −1 . The release kinetics of SIM were also tracked using HPLC, while the concentration of SIM was too low and remained undetectable in the released solution due to the strong hydrophobicity [ 39 ]. Figure 2b shows the FTIR spectra of SIM and the prepared samples, the FTIR spectrum of ACMP/SIM did not obviously show the characteristic peaks of SIM, which is due to the low content of SIM in ACMP/SIM.…”

Section: Resultsmentioning

confidence: 99%

Amorphous calcium magnesium phosphate nanocomposites with superior osteogenic activity for bone regeneration

Jiang

Tan

et al. 2021

Regenerative Biomaterials

View full text Add to dashboard Cite

The seek of bioactive materials for promoting bone regeneration is a challenging and long-term task. Functionalization with inorganic metal ions or drug molecules are considered effective strategies to improve the bioactivity of various existing biomaterials. Herein, amorphous calcium magnesium phosphate (ACMP) nanoparticles and simvastatin (SIM)-loaded ACMP (ACMP/SIM) nanocomposites were developed via a simple coprecipitation strategy. The physiochemical property of ACMP/SIM were explored using transmission electron microscope (TEM), Fourier transform infrared spectroscopy (FTIR), powder X-ray diffraction (XRD) and high performance liquid chromatograph (HPLC), and the role of Mg2+ in the formation of ACMP/SIM was revealed using X-ray absorption near-edge structure (XANES). After that, the transformation process of ACMP/SIM in simulated body fluid (SBF) was also tracked to simulate and explore the in vivo mineralization performance of materials. We find that ACMP/SIM releases ions of Ca2+, Mg2+ and PO43-, when it is immersed in SBF at 37 °C, and a phase transformation occured during which the initially amorphous ACMP turns into self-assembled hydroxyapatite (HAP). Furthermore, ACMP/SIM displays high cytocompatibility and promotes the proliferation and osteogenic differentiation of MC3T3-E1 cells. For the in vivo studies, lamellar ACMP/SIM/Collagen scaffolds with aligned pore structures were prepared and used to repair a rat defect model in calvaria. ACMP/SIM/Collagen scaffolds show a positive effect in promoting the regeneration of calvaria defect after 12 weeks. The bioactive ACMP/SIM nanocomposites are promising as bone repair materials. Considering the facile preparation process and superior in vitro/vivo bioactivity, the as-prepared ACMP/SIM would be a potential candidate for bone related biomedical applications.

show abstract

Calcium Supplement by Tetracycline guided amorphous Calcium Carbonate potentiates Osteoblast promotion for Synergetic Osteoporosis Therapy

Cited by 26 publications

References 44 publications

Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy

Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy

Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures

Amorphous calcium magnesium phosphate nanocomposites with superior osteogenic activity for bone regeneration

Contact Info

Product

Resources

About